Abbott, the global leader in screening blood and plasma, partnered with Blood Centers of America, the largest blood supplier network in the U.S., to launch a mixed reality experience for blood donors in June 2023. Results from a pilot study reveal that mixed reality “is an innovative technology that holds promise to increase donor engagement, satisfaction, and retention,” researchers said.
The Biden administration is sending drugmakers opening offers for the U.S. Medicare program’s first ever price negotiations on Thursday, the White House said in a statement.
Despite strong sales of its blockbuster drug Dupixent, Sanofi reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.
The Japanese pharma now expects the AstraZeneca-partnered Enhertu to bring in approximately $2.61 billion for the fiscal year 2023, this time driven by growth outside the United States.
The Inflation Reduction Act’s Drug Price Negotiation Program will erode only a small portion of global biopharma revenues and is unlikely to cause significant cuts to research and development, find researchers.
Laboratory operator Quest Diagnostics beat fourth-quarter estimates and forecast 2024 sales above Wall Street expectation on Thursday, as it benefits from strong demand for its routine testing kits, excluding COVID products.
The company said its results showed it was overcoming a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs.
The case was set to go to trial on Feb. 20 and instead, will now be dismissed, the British drugmaker said in a statement.
The Swiss pharma’s fourth-quarter sales fell short of analysts’ estimates on Wednesday, as the company said it dropped a late-stage blood cancer hopeful after failing a Phase III study.
The company said the job cuts would impact both full-time employees and contractors.